Optimal qMSP cutoff value for MGMT promoter methylation in glioblastoma and its validation for clinical significance
Abstract Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor, with limited survival despite multimodal treatment strategies. O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation is a well-established predictive biomarker for response to temozolomide (TMZ...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2025-11-01
|
| Seri Bilgileri: | BMC Cancer |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12885-025-15225-2 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|